Concepedia

Author

Ioannis Xanthakis

Aristotle University of Thessaloniki

Also Known As

I Xanthakis, I. Xanthakis, IOANNIS XANTHAKIS, Ioannis Xanthakis, Xanthakis, Ioannis

49

Publications

987

Citations

16

H-Index

16

Concepts

All Affiliations

Aristotle University of ThessalonikiPapageorgiou General HospitalMetropolitan HospitalUniversity Hospital of IoanninaHospital Agioi Anargyroi
IX

About

Ioannis Xanthakis is an author at Aristotle University of Thessaloniki specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

157

2

Gastroenterology

1

1

47

3

Immunology

1

1

47

4

Pathology

1

1

47

5

Pharmacology

1

1

13

Ioannis Xanthakis

×

17

Publications

920

Citations

16

H-Index

YearCitations

Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations

Georgios Tsaousis, Eirini Papadopoulou, Angela Apessos,

BMC Cancer

2019

127

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

George Pentheroudakis, Vassiliki Kotoula, Wendy De Roock,

BMC Cancer

2013

111

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Aristotelis Bamias, Urania Dafni, Alexandra Karadimou,

Annals of Oncology

2012

97

Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study

Evangelia Razis, Evangelos Briasoulis, Eleni Vrettou,

BMC Cancer

2008

92

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

Evangelos Briasoulis, Gerasimos Aravantinos, George Kouvatseas,

BMC Cancer

2013

76

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides, George Papaxoinis, Konstantine T. Kalogeras,

BMC Cancer

2012

76

Regression of Inflammatory Myofibroblastic Tumor of the Gastrointestinal Tract Under Infliximab Treatment

Georgios Germanidis, Ioannis Xanthakis, Ioannis Tsitouridis,

Digestive Diseases and Sciences

2005

47

Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.

Dimitrios Krikelis, Evangelia Skoura, Vassiliki Kotoula,

PubMed

2014

37

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

George Pentheroudakis, Vassiliki Kotoula, Elena Fountzilas,

BMC Cancer

2014

35

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab

George Fountzilas, Christos Christodoulou, Mattheos Bobos,

Journal of Translational Medicine

2012

35

Page 1